# Therapeutic Advances in Gastroenterology 9(4)

Michail, S., Durbin, M., Turner, D., Griffiths, A., Mack, D., Hyams, J. et al. (2012) Alterations in the gut microbiome of children with severe ulcerative colitis. Inflamm Bowel Dis 18: 1799–1808.

Michielan, A. and D’Inca, R. (2015) Intestinal permeability in inflammatory bowel disease: pathogenesis, clinical evaluation, and therapy of leaky gut. Mediators Inflamm 2015: 628157.

Miele, E., Pascarella, F., Giannetti, E., Quaglietta, L., Baldassano, R. and Staiano, A. (2009) Effect of a probiotic preparation (VSL#3) on induction and maintenance of remission in children with ulcerative colitis. Am J Gastroenterol 104: 437–443.

Mimura, T., Rizzello, F., Helwig, U., Poggioli, G., Schreiber, S., Talbot, I. et al. (2004) Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis. Gut 53: 108–114.

Moayyedi, P., Surette, M., Kim, P., Libertucci, J., Wolfe, M., Onischi, C. et al. (2015) Fecal microbiota transplantation induces remission in patients with active ulcerative colitis in a randomized controlled trial. Gastroenterology 149: 102–109 e106.

Modi, S., Collins, J. and Relman, D. (2014) Antibiotics and the gut microbiota. J Clin Invest 124: 4212–4218.

Moehle, C., Ackermann, N., Langmann, T., Aslanidis, C., Kel, A., Kel-Margoulis, O. et al. (2006) Aberrant intestinal expression and allelic variants of mucin genes associated with inflammatory bowel disease. J Mol Med (Berl) 84: 1055–1066.

Molodecky, N., Soon, I., Rabi, D., Ghali, W., Ferris, M., Chernoff, G. et al. (2012) Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology 142: 46–54.e42; quiz e30.

Mowat, C., Cole, A., Windsor, A., Ahmad, T., Arnott, I., Driscoll, R. et al. (2011) Guidelines for the management of inflammatory bowel disease in adults. Gut 60: 571–607.

Nagalingam, N. and Lynch, S. (2012) Role of the microbiota in inflammatory bowel diseases. Inflamm Bowel Dis 18: 968–984.

Naganuma, M., Iizuka, B., Torii, A., Ogihara, T., Kawamura, Y., Ichinose, M. et al. (2001) Appendectomy protects against the development of ulcerative colitis and reduces its recurrence: results of a multicenter case-controlled study in Japan. Am J Gastroenterol 96: 1123–1126.

Nicholson, J., Holmes, E., Kinross, J., Burcelin, R., Gibson, G., Jia, W. et al. (2012) Host-gut microbiota metabolic interactions. Science 336: 1262–1267.

Nickerson, K., Chanin, R. and McDonald, C. (2015) Deregulation of intestinal anti-microbial defense by the dietary additive, maltodextrin. Gut Microbes 6: 78–83.

Norman, J., Handley, S., Baldridge, M., Droit, L., Liu, C., Keller, B. et al. (2015) Disease-specific alterations in the enteric virome in inflammatory bowel disease. Cell 160: 447–460.

Obih, C., Wahbeh, G., Lee, D., Braly, K., Giefer, M., Shaffer, M. et al. (2016) Specific carbohydrate diet for pediatric inflammatory bowel disease in clinical practice within an academic IBD center. Nutrition 32: 418–425.

Ockenga, J., Borchert, K., Stuber, E., Lochs, H., Manns, M. and Bischoff, S. (2005) Glutamine-enriched total parenteral nutrition in patients with inflammatory bowel disease. Eur J Clin Nutr 59: 1302–1309.

Ogura, Y., Bonen, D., Inohara, N., Nicolae, D., Chen, F., Ramos, R. et al. (2001) A frameshift mutation in NOD2 associated with susceptibility to Crohn’s disease. Nature 411: 603–606.

O’Hara, A. and Shanahan, F. (2006) The gut flora as a forgotten organ. EMBO Rep 7: 688–693.

Ott, S., Musfeldt, M., Wenderoth, D., Hampe, J., Brant, O., Fölsch, U. et al. (2004) Reduction in diversity of the colonic mucosa associated bacterial microflora in patients with active inflammatory bowel disease. Gut 53: 685–693.

Parkes, G., Whelan, K. and Lindsay, J. (2014) Smoking in inflammatory bowel disease: impact on disease course and insights into the aetiology of its effect. J Crohns Colitis 8: 717–725.

Parkes, M. (2012) Evidence from genetics for a role of autophagy and innate immunity in IBD pathogenesis. Dig Dis 30: 330–333.

Pastor Rojo, O., Lopez San Roman, A., Albeniz Arbizu, E., De La Hera Martinez, A., Ripoll Sevillano, E. and Albillos Martinez, A. (2007) Serum lipopolysaccharide-binding protein in endotoxemic patients with inflammatory bowel disease. Inflamm Bowel Dis 13: 269–277.

Penders, J., Thijs, C., Vink, C., Stelma, F., Snijders, B., Kummeling, I. et al. (2006) Factors influencing the composition of the intestinal microbiota in early infancy. Pediatrics 118: 511–521.

Peng, J., Shen, J. and Ran, Z. (2014) Novel agents in the future: therapy beyond anti-TNF agents in inflammatory bowel disease. J Dig Dis 15: 585–590.

Petrof, E., Gloor, G., Vanner, S., Weese, S., Carter, D., Daigneault, M. et al. (2013) Stool substitute transplant therapy for the eradication of clostridium difficile infection: ‘repoopulating’ the gut. Microbiome 1: 3.

Petrof, E. and Khoruts, A. (2014) From stool transplants to next-generation microbiota therapeutics. Gastroenterology 146: 1573–1582.

622 http://tag.sagepub.com